Watch on YouTube
(Embed)
3
0
Genre: Science & Technology
License: Standard YouTube license
Family friendly? Yes
Shared September 27, 2026
TG4050 is a personalized cancer vaccine using AI to target unique tumor mutations. By sequencing a patient's tumor, the AI identifies specific neoantigens, creating a navigational map for the immune system to locate and destroy remaining malignant cells. In a Phase 1 trial, 100% of patients receiving TG4050 remained disease-free after 3 years, versus relapses in the control group. This virus-based delivery system trains T-cells to hunt hidden threats, preventing relapse after surgery. While the sample size is limited, the tech represents a paradigm shift in oncology. Larger trials are now underway to confirm if this AI-driven platform can consistently prevent cancer recurrence.
570K views
1 view
